Table 3.
Multivariate analysis for OS and LRPFS
| OS |
LRPFS |
|||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| PTV volume (mL) | ||||
| ≤412 | - | - | ||
| >412 | 2.05 (1.08–3.90) | 0.028 | 1.59 (0.89–2.86) | 0.116 |
| Pre-CCRT NLR | ||||
| ≤1.64 | - | - | ||
| >1.64 | 1.28 (0.51–3.24) | 0.600 | 0.96 (0.41–2.25) | 0.919 |
| Pre-CCRT PLR | ||||
| ≤115 | - | - | ||
| >115 | 0.78 (0.35–1.76) | 0.553 | 0.71 (0.32–1.54) | 0.385 |
| Post-CCRT NLR | ||||
| ≤3.12 | - | - | ||
| >3.12 | 1.60 (0.68–3.81) | 0.285 | 1.56 (0.70–3.52) | 0.279 |
| Post-CCRT PLR | ||||
| ≤141 | - | - | ||
| >141 | 2.18 (0.89–5.33) | 0.088 | 1.79 (0.82–3.90) | 0.140 |
| NLR change | ||||
| ≤1.61 | - | - | ||
| >1.61 | 3.17 (1.16–8.69) | 0.025 | 1.71 (0.72–4.09) | 0.227 |
| PLR change | ||||
| ≤1.67 | - | - | ||
| >1.67 | 0.39 (0.15–1.03) | 0.057 | 0.69 (0.31–1.54) | 0.361 |
OS, overall survival; LRPFS, locoregional progression-free survival; HR, hazard ratio; CI, confidence interval; PTV, planning target volume; CCRT, concurrent chemoradiotherapy; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; NLR change, dividing the post-CCRT NLR by the pre-CCRT NLR; PLR change, dividing the post-CCRT PLR by the pre-CCRT PLR.